Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections-Reference-Cited by-同舟云学术

Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections

Published:1996-12 Issue:12 Volume:15 Page:913-921
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur. J. Clin. Microbiol. Infect. Dis.

Author:

Falagas M. E.,Barefoot L.,Griffith J.,Ruthazar R.,Snydman D. R.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF01690508.pdf

Reference29 articles.

1. Bartlett JG: Intra-abdominal sepsis. Medical Clinics of North America 1995, 79: 599–617.

2. Swartz MN: Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R (ed): Principles and practice of infectious diseases. Churchill Livingstone, New York, 1995, p. 909–928.

3. Condon RE, Wittmann DH: Approach to the patient with intra-abdominal infection. In: Gorbach SL, Bartlett JG, Blacklow NR (ed): Infectious diseases. Saunders, Philadelphia, 1992: 654–660.

4. Solomkin JS, Miyagawa CI: Principles of antibiotic therapy. Surgical Clinics of North America 1994, 74: 497–517.

5. Gorbach SL: Antibiotic treatment of anaerobic infections. Clinical Infectious Diseases 1994,18, Supplement 4: 305.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment;BMC Infectious Diseases;2019-11-21

2. Surgical Infectious Disease;Abernathy's Surgical Secrets;2018

3. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK;Journal of Medical Economics;2017-06-08

4. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections;BMC Infectious Diseases;2017-04-28

5. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection;Antimicrobial Agents and Chemotherapy;2016-08-08